PREDICTORS OF IBRUTINIB-ASSOCIATED ATRIAL FIBRILLATION: 5-YEAR FOLLOW-UP OF A PROSPECTIVE STUDY.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3126
Abstract: Ibrutinib-associated atrial fibrillation (IRAF) emerged among the adverse events of major interests in ibrutinib-treated patients as real-world studies showed a higher incidence compared to clinical trials. We prospectively analysed predictors of IRAF in 43 single-center… read more here.
Keywords: fibrillation year; ibrutinib associated; predictors ibrutinib; associated atrial ... See more keywords
Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates
Sign Up to like & getrecommendations! Published in 2021 at "BMJ Case Reports"
DOI: 10.1136/bcr-2020-237085
Abstract: Herein, we report a case of a 68-year-old woman receiving ibrutinib for chronic lymphocytic leukaemia, who presented with septic shock and a progressive necrotic lesion on her nose. Surgical pathology of the nasal lesion revealed… read more here.
Keywords: ibrutinib associated; lesion pulmonary; associated necrotic; nasal lesion ... See more keywords
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s377697
Abstract: Abstract Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the… read more here.
Keywords: ibrutinib; ibrutinib associated; associated cardiotoxicity; cardiotoxicity ... See more keywords
Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom’s Macroglobulinemia and Review of the Literature
Sign Up to like & getrecommendations! Published in 2017 at "Dermatology Reports"
DOI: 10.4081/dr.2017.6976
Abstract: Waldenstrom's macroglobulinamia (WM) is a rare malignant lymphoproliferative disorder, characterized by monoclonal IgM paraproteinemia and neoplastic proliferation of malignant lymphoplasmacytoid cells in the bone marrow. Traditionally, WM has been treated with modalities similar to those… read more here.
Keywords: literature; ibrutinib; ibrutinib associated; review ... See more keywords